Veterinary Anti-infectives Global Market Report 2025

The veterinary anti-infectives market size has grown strongly in recent years. It will grow from $5.54 billion in 2024 to $6.02 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to increasing pet ownership, prevalence of infectious diseases, advancements in veterinary medicine, rising awareness, government initiatives.

The veterinary anti-infectives market size is expected to see strong growth in the next few years. It will grow to $8.69 billion in 2029 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to continued pet population growth, emerging zoonotic diseases, globalization of pet trade, increasing veterinary healthcare expenditure. Major trends in the forecast period include technological advancements, increasing adoption of biologicals, integration of telehealth in veterinary services, focus on natural and herbal alternatives, expansion of e-commerce in veterinary pharmaceuticals, collaborations and partnerships.

The forecast of 9.6% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariffs on sterilization inputs and fermentation-based actives could reduce production capacity and delay the launch of new anti-infective formulations. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

An increase in pet ownership is anticipated to drive the growth of the veterinary anti-infectives market in the future. Pet ownership refers to having dogs, cats, or other domestic animals at home. More young individuals are adopting pets, viewing them as family members, and many owners are motivated by the pets' companionship, loyalty, and ability to alleviate loneliness. For instance, in 2022, data from Animal Medicines Australia, a non-governmental organization based in Australia, indicated a significant rise in pet ownership, with the number of pet owners reaching 28,730.8, compared to 39% in 2021. This marks a 24% increase, reflecting a strong upward trend in pet adoption and investment in pet care. The rise in pet ownership highlights the growing appeal of pets within Australian households. Thus, the increase in pet ownership is fueling demand for the veterinary anti-infectives market.

The veterinary anti-infectives market is expected to witness growth due to the increasing trend of rising livestock production. Livestock, including cattle, sheep, pigs, chickens, and goats, are raised for various purposes, such as food production, labor, and companionship. Veterinary anti-infectives play a crucial role in treating infections in animals, ensuring their health and well-being, and preventing and controlling diseases. According to the National Agricultural Statistics Service, in the US, there were approximately 28. 9 million beef cows, 9. 4 million dairy cows, and an estimated 11. 1 million cattle on feed in 2022. The expanding livestock production contributes to the growth of the veterinary anti-infectives market.

Major players in the veterinary anti-infectives market are forming strategic partnerships to address the threat of antimicrobial resistance (AMR). Strategic partnerships involve companies utilizing each other's strengths and resources to achieve mutual benefits and success. For example, in November 2022, the Food and Agriculture Organization of the United Nations (FAO), the UN Environment Programme (UNEP), the World Health Organization (WHO), and the World Organization for Animal Health (WOAH), collectively known as the Quadripartite, launched the Antimicrobial Resistance Multi-Stakeholder Partnership Platform. This initiative aims to highlight the risks that AMR poses to humans, animals, plants, ecosystems, and livelihoods, as well as to ensure that the increasing challenges and consequences of antimicrobial resistance are addressed on a global scale.

The term veterinary anti-infective encompasses a wide range of methods aimed at preventing and treating illnesses in animals. These products are utilized in veterinary medicine to promote the health and well-being of both livestock and pets, as well as to control disease outbreaks within animal populations.

The main types of drug classes in veterinary anti-infectives include antimicrobial agents, antiviral agents, antifungal agents, and others. Antimicrobial agents are substances, either natural or synthetic, that function by killing or inhibiting the growth of microorganisms such as bacteria, fungi, and algae. Various species, including livestock animals and companion animals, are involved in the administration of these drugs through oral, parenteral, and topical modes. Distribution channels for veterinary anti-infectives include veterinary hospitals, veterinary clinics, pharmacies, and other relevant outlets.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The rapid escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a considerable impact on the veterinary healthcare sector, particularly in the supply of pharmaceuticals, medical devices, and animal care products. Increased duties on imported veterinary medicines, diagnostic equipment, surgical tools, and pet care supplies have driven up operational costs for veterinary clinics, animal hospitals, and livestock health providers, forcing them to either raise service charges or absorb reduced profit margins. The livestock and agricultural industries are facing similar pressures, as tariffs on feed additives, vaccines, and breeding equipment push up production costs and complicate animal health management. Furthermore, retaliatory tariffs in major export markets have weakened demand for U.S.-manufactured veterinary products, adding to revenue challenges. To navigate these headwinds, the sector must now focus on local sourcing, preventive healthcare strategies, and digital veterinary solutions to control costs while continuing to deliver quality animal care.

The veterinary anti-infectives market research report is one of a series of new reports that provides veterinary anti-infectives market statistics, including veterinary anti-infectives industry global market size, regional shares, competitors with veterinary anti-infectives market share, detailed veterinary anti-infectives market segments, market trends, and opportunities, and any further data you may need to thrive in the veterinary anti-infectives industry. This veterinary anti-infectives market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Strategic partnerships are another significant approach adopted by major players in the veterinary anti-infectives market to address the threat of antimicrobial resistance. In November 2022, The Food and Agriculture Organization of the United Nations (FAO), the UN Environment Programme (UNEP), the World Health Organization (WHO), and the World Organization for Animal Health (WOAH) jointly launched The Antimicrobial Resistance Multi-Stakeholder Partnership Platform. This initiative aims to highlight the global threat posed by antimicrobial resistance and ensure a coordinated international effort to address its challenges and consequences.

In June 2022, Ceva Santé Animale, a multinational animal health company based in France, acquired Artemis Technologies, Inc., a Canada-based oral rabies vaccine manufacturer, for an undisclosed amount. This strategic acquisition enhances Ceva's rabies portfolio and expands its market footprint in North America.

Major companies operating in the veterinary anti-infectives market include Bayer AG, C. H. Boehringer Sohn AG & Co. KG, Ceva Santé Animale, Elanco Animal Health Incorporated, Zoetis Inc., Vetoquinol S. A., Merck & Co., Phibro Animal Health, Aspen Veterinary Resources Ltd., Bimeda Animal Health Limited, Dechra Pharmaceuticals Plc, Intervet International B. V., Oceanic Pharmachem Pvt. Ltd., Virbac Ltd., Indian Immunologicals Ltd. (IIL), Norbrook Laboratories Ltd., Ashish Life Science Pvt. Ltd., Kyoritsu Seiyaku Corporation, Tianjin Ringpu Bio-Technology Co. Ltd., HIPRA, Zydus Animal Health and Investments Limited, China Animal Husbandry Group, ZOOVETVARU Ltd., Magnum Veterinaaria Ltd., Inovet (V. M. D. nv/sa), Chanelle Pharmaceuticals Manufacturing Ltd., Huvepharma Inc., Veyx Pharma GmbH, Biovet Pvt. Ltd., Laboratorios Ovejero SA, Laboratorios Syva S. A.

North America was the largest region in the veterinary anti-infectives market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veterinary anti-infectives market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the veterinary anti-infectives market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The veterinary anti-infectives market consists of revenues earned by entities by providing antibacterial that are used to prevent and treat animal diseases such as infections. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.